Clinical Trial Update: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study of E7386 in combination with pembrolizumab in previously treated solid tumors (melanoma, hepatocellular carcinoma, and colorectal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Hepatocellular Carcinoma
• Melanoma

Drugs mentioned

• E7386
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eisai Inc. | Conditions: Melanoma, Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-24